

Prism for PTSD

Neuroscience-based innovation
for treating mental disorders.



GrayMatters
Health



EMPOWERING FOR YOU. PERSONAL FOR YOUR PATIENT.

Prism for PTSD™ is a neuroscience-based, prescription therapy FDA-cleared to treat post-traumatic stress disorder (PTSD). Combining innovative software with an affordable EEG headset, Prism for PTSD pioneers a new treatment modality called self-neuromodulation. Self, because the patient is in control, expertly guided by you, their trusted healthcare provider, and Prism. Modulation, because the patient learns to regulate an amygdala-based biomarker that measures brain activity associated with their PTSD symptoms.

VALUE FOR MENTAL HEALTH CLINICS

GMH is currently deploying Prism at select clinics in the USA.

- **Operational simplicity.** With installation and training taking less than 4 hours, train in the morning and treat patients the same afternoon.
- **Reduced costs and expanded access to care.** Prism can be operated by a non-MD, such as an NP, social worker or technician.
- **Automated report generation.** Prism collects data to automatically generate textual and analytical reports.
- **Engaged patient experience.** Personalized, non-trauma-based treatment that helps patients gain a sense of agency over their PTSD, and their lives.

CLINICAL RESULTS

The Prism for PTSD multi-center clinical study¹ demonstrated the following results 3 months after the 15-session regimen (5 months from baseline):

Efficacy

- 67% of patients overall demonstrated clinically significant symptom improvement, with >80% response rate in some sub-populations.
- Significant improvement in sleep, as measured by PHQ-9 and CAPS-5.
- 32% experienced remission, with >50% in some sub-populations.
- 90% patient compliance.

Safety

- Side effects were mild and self-resolved after treatment.

INDICATION FOR USE

Prism is a neurofeedback software device intended for relaxation and stress reduction through the use of EEG biofeedback. The device is indicated as an adjunctive treatment of symptoms associated with posttraumatic stress disorder (PTSD), to be used under the direction of a healthcare professional, together with other pharmacological and/or non-pharmacological interventions.

¹ Fruchter et al. [Amygdala-derived-EEG-fMRI-pattern neurofeedback for the treatment of chronic post-traumatic stress disorder. A prospective, multicenter, multinational study evaluating clinical efficacy.](#) Psychiatry Research, Volume 333, 2024

RICH PATIENT EXPERIENCE


During Prism therapy, a computer simulation and EEG headset create an immersive environment for training individuals to gain control over digital biomarker activity associated with PTSD. Prism for PTSD uses an amygdala-based biomarker since research has shown that PTSD is associated with hyper-activity of the amygdala.

During a Prism session, the patient watches a computer simulation with agitated avatars, while an EEG headset measures their brain activity in real-time, like a fitness tracker measures heart rate. The patient is instructed to identify a mental strategy – an experience, memory or emotion – to make the avatars sit down.

During this time, Prism reads the signal from the EEG headset and computes the amygdala-based biomarker. Once the patient engages with a mental strategy that reduces the amygdala-biomarker level, the avatars will gradually sit and quiet down. Think of it like placing a mirror in front of this brain activity. This personal mental strategy is practiced in the clinic and may be applied in everyday life to help control PTSD symptoms.

PRISM REGIMEN

- 15 sessions, over 8 weeks
- 30-45-minutes/session
- Booster sessions, as needed



SETUP

Prism for PTSD includes a laptop installed with the Prism software, computer monitor, and cloud services. Also provided is an FDA-approved, off-the-shelf wireless EEG headset. Installation and training are performed by the GMH team and requires less than four hours.

Prism requires a small quiet room, stationary table and chair, wired Internet connection and a trained Prism healthcare professional to monitor the patient sessions. During most of the treatment itself, it is possible to monitor the patient session from a remote computer in a separate room.

TECHNOLOGY

The company's core technology is the world's first digital brain biomarkers associated with mental disorders. This innovation was developed by applying advanced machine learning models to register amygdala fMRI data with an accessible and low-cost modality, EEG.

GMH's patented biomarker technology has been extensively researched and featured in peer-reviewed publications, led by Professor Talma Hendler, MD, PhD., renowned psychiatrist and neuroscientist, and her team at Tel Aviv University.

COMPANY OVERVIEW

[GrayMatters Health](#) (GMH) is developing and marketing solutions for treating mental disorders, based on the world's first digital brain biomarkers. The company won the [2023 USA Prix Galien Best Startup award](#).

A team of professionals is leading the USA rollout including dedicated experts in sales, marketing, customer support and reimbursement.

GMH is collaborating with leading mental health institutions to evaluate expanding the Prism therapy portfolio. In addition, data from Prism treatments is being used to develop future personalization features including patient experience insights and therapy prediction.



GrayMatters
Health